Sector
PharmaceuticalsOpen
₹25.68Prev. Close
₹25.43Turnover(Lac.)
₹4.02Day's High
₹26.1Day's Low
₹25.552 Week's High
₹4252 Week's Low
₹22.25Book Value
₹-7.53Face Value
₹10Mkt Cap (₹ Cr.)
111.19P/E
0EPS
0Divi. Yield
07 Aug 2024
12:00 AM
Board Meeting
Agenda : Audited Result
28 Nov 2023
12:00 AM
AGM
Announcement Date: 28 Nov, 2023
28 Nov 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 43.18 | 43.18 | 43.18 | 43.18 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 44.62 | 62.17 | -9.14 | -22.71 |
Net Worth | 87.8 | 105.35 | 34.04 | 20.47 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 85.33 | 66.83 | 34.79 | 124.18 |
yoy growth (%) | 27.67 | 92.06 | -71.97 | -3 |
Raw materials | -81.21 | -55.96 | -26.97 | -89.85 |
As % of sales | 95.17 | 83.73 | 77.51 | 72.35 |
Employee costs | -14.44 | -11.37 | -10.3 | -10.21 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -24.2 | -14.2 | -7.95 | 9.22 |
Depreciation | -0.23 | -0.23 | -0.41 | -0.57 |
Tax paid | 6.09 | 3.99 | 3.69 | -2.71 |
Working capital | 1.81 | -30.33 | -7.03 | -6.6 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 27.67 | 92.06 | -71.97 | -3 |
Op profit growth | 100.53 | 26.74 | -166.69 | -270.92 |
EBIT growth | 105.36 | 30.82 | -155.99 | -299.94 |
Net profit growth | 77.37 | 139.6 | -165.46 | -204.85 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,834.05 | 156.48 | 4,31,400.43 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,846.55 | 84.17 | 1,54,622.17 | 518 | 0.51 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,451.15 | 27.46 | 1,16,239.89 | 1,178.16 | 0.9 | 3,969.86 | 360.73 |
Dr Reddys Laboratories Ltd DRREDDY | 1,289.35 | 22.49 | 1,08,166.38 | 1,882.1 | 0.62 | 6,678.8 | 322.47 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,266.2 | 65.51 | 1,07,174.09 | 460 | 0.88 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Y K Gupta
Company Sec. & Compli. Officer
Sandip K Lal
Independent Director
Alka Sharma
Independent Director
Mohd Aslam
Independent Director
Sudhanshu Vrati
Independent Director
Madhu Dikshit
Managing Director
Sanjay Kumar Mishra
Independent Director
Pankaj Kumar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bharat Immunological & Biological Corporation Ltd
Summary
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology. BIBCOL was incorporated in 1989. The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.The companys manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh. BIBCL installed a plant of 100 mln units. Commercial production of the OPV started from Jan96.The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US.In year 2006, the facility was up graded to meet the WHO cGMP & revised schedule M of Drugs & Cosmetics Act. In 2016, BIBCOL switched over to bOPV from tOPV . To add in product line, company diversified into Plasma derived medicines, and Oral Cholera Vaccine.
Read More
What is the Bharat Immunological & Biological Corporation Ltd share price today?
The Bharat Immunological & Biological Corporation Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹25.75 today.
What is the Market Cap of Bharat Immunological & Biological Corporation Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bharat Immunological & Biological Corporation Ltd is ₹111.19 Cr. as of 23 Jan ‘25
What is the PE and PB ratio of Bharat Immunological & Biological Corporation Ltd?
The PE and PB ratios of Bharat Immunological & Biological Corporation Ltd is 0 and -3.37 as of 23 Jan ‘25
What is the 52 Week High and Low of Bharat Immunological & Biological Corporation Ltd?
The 52-week high/low is the highest and lowest price at which a Bharat Immunological & Biological Corporation Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bharat Immunological & Biological Corporation Ltd is ₹22.25 and ₹42 as of 23 Jan ‘25
What is the CAGR of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd's CAGR for 5 Years at 27.06%, 3 Years at -18.40%, 1 Year at -21.37%, 6 Month at -8.26%, 3 Month at -1.40% and 1 Month at 8.07%.
What is the shareholding pattern of Bharat Immunological & Biological Corporation Ltd?
The shareholding pattern of Bharat Immunological & Biological Corporation Ltd is as follows:
Promoters - 59.25 %
Institutions - 0.00 %
Public - 40.75 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
